On August 19, 2022, Public Joint-Stock Company "Human Stem Cells Institute" closed the transaction. The company amended the terms of the transaction. The company issued 7,645,451 shares at issue price of RUB 80 for a gross proceeds of RUB 611636080.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.54 RUB | +1.43% |
|
-.--% | -.--% |
26/04 | Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 50.64M | |
+17.11% | 83.02B | |
-25.70% | 73.65B | |
+0.28% | 26.5B | |
+4.70% | 17.72B | |
-8.71% | 17.49B | |
+4.87% | 16.06B | |
+79.85% | 13.83B | |
+73.90% | 12.84B | |
-26.49% | 12.73B |
- Stock Market
- Equities
- ISKJ Stock
- News Human Stem Cells Institute
- Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received RUB 611.63608 million in funding from PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy